| [1] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J].CA Cancer J Clin,2023,73(1): 17-48. DOI:10.3322/caac.21763. |
| [2] |
Masci D, Naro C, Puxeddu M, et al. Recent advances in drug discovery for triple-negative breast cancer treatment[J].Molecules,2023,28(22): 7513. DOI:10.3390/molecules28227513. |
| [3] |
谢露露, 丁江华. 免疫治疗在晚期三阴性乳腺癌中的应用进展[J].国际肿瘤学杂志,2023,50(11): 672-676. DOI:10.3760/cma.j.cn371439-20230722-00127. |
| [4] |
Adrada BE, Moseley TW, Kapoor MM, et al. Triple-negative breast cancer: histopathologic features, genomics, and treatment[J].Radiographics,2023,43(10): e230034. DOI:10.1148/rg.230034. |
| [5] |
Hadebe B, Harry L, Ebrahim T, et al. The role of PET/CT in breast cancer[J].Diagnostics,2023,13(4): 597. DOI:10.3390/diagnostics 13040597. |
| [6] |
McDonald ES, Clark AS, Tchou J, et al. Clinical diagnosis and management of breast cancer[J].J Nucl Med,2016,57 Suppl 1: 9S-16S. DOI:10.2967/jnumed.115.157834. |
| [7] |
Andryszak N, Świniuch D, Wójcik E, et al. Head-to-head comparison of [18F]PSMA-1007 and [18F]FDG PET/CT in patients with triple-negative breast cancer[J].Cancers (Basel),2024,16(3): 667. DOI:10.3390/cancers16030667. |
| [8] |
Romeo V, Kapetas P, Clauser P, et al. A simultaneous multiparametric18F-FDG PET/MRI radiomics model for the diagnosis of triple negative breast cancer[J].Cancers (Basel),2022,14(16): 3944. DOI:10.3390/cancers14163944. |
| [9] |
Arslan E, Çermik TF, Trabulus FDC, et al. Role of18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer[J].Nucl Med Commun,2018,39(7): 680-690. DOI:10.1097/MNM.0000000000000856. pmid:29893750 |
| [10] |
Seban RD, Arnaud E, Loirat D, et al. [18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab[J].Eur J Nucl Med Mol Imaging,2023,50(13): 4024-4035. DOI:10.1007/s00259-023-06394-y. |
| [11] |
Gao Y, Yin L, Ma L, et al. Comparative analysis of metabolic cha-racteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using18F-FDG PET/CT imaging[J].Cancer Imaging,2024,24(1): 166. DOI:10.1186/s40644-024-00812-6. |
| [12] |
Roy M, Fowler AM, Ulaner GA, et al. Molecular classification of breast cancer[J].PET Clin,2023,18(4): 441-458. DOI:10.1016/j.cpet.2023.04.002. pmid:37268505 |
| [13] |
康佳, 吴桐, 张蕾, 等. 不同分子分型乳腺癌的多模态超声特征和临床病理对照研究[J].中华超声影像学杂志,2020,29(4): 330-336. DOI:10.3760/cma.j.cn131148-20190926-00591. |
| [14] |
Costantini M, Belli P, Bufi E, et al. Association between sonographic appearances of breast cancers and their histopathologic features and biomarkers[J].J Clin Ultrasound,2016,44(1): 26-33. DOI:10.1002/jcu.22312. pmid:26402438 |
| [15] |
Sannomiya N, Hattori Y, Ueda N, et al. Correlation between ultrasound findings of tumor margin and clinicopathological findings in patients with invasive ductal carcinoma of the breast[J].Yonago Acta Med,2016,59(2): 163-168. pmid:27493488 |
| [16] |
Wang D, Zhu K, Tian J, et al. Clinicopathological and ultrasonic features of triple-negative breast cancers: a comparison with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers[J].Ultrasound Med Biol,2018,44(5): 1124-1132. DOI:10.1016/j.ultrasmedbio.2018.01.013. pmid:29482888 |
| [17] |
Ian TWM, Tan EY, Chotai N. Role of mammogram and ultrasound imaging in predicting breast cancer subtypes in screening and symptomatic patients[J].World J Clin Oncol,2021,12(9): 808-822. DOI:10.5306/wjco.v12.i9.808. pmid:34631444 |
| [18] |
刘晓瑜, 林翠君, 黄洁, 等. 不同分子分型乳腺癌的超声、MRI及乳腺X射线摄影特征的诊断价值[J].国际放射医学核医学杂志,2024,48(2): 74-81. DOI:10.3760/cma.j.cn121381-202212013-00349. |
| [19] |
Moreel L, Betrains A, Doumen M, et al. Diagnostic yield of combined cranial and large vessel PET/CT, ultrasound and MRI in giant cell arteritis: a systematic review and meta-analysis[J].Autoimmun Rev,2023,22(7): 103355. DOI:10.1016/j.autrev.2023.103355. |
| [20] |
刘春海, 周虎, 刘文静, 等. 超声联合PET/CT及CA153监测乳腺癌术后颈部淋巴结转移的价值[J].中国超声医学杂志,2023,39(3): 261-265. DOI:10.3969/j.issn.1002-0101.2023.03.006. |